Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18263277 | LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES | Non-Final OA | Merck Sharp & Dohme LLC |
| 18014004 | MODIFIED YEAST HOST CELLS USEFUL FOR PRODUCING ISOPRENOL | Final Rejection | The Regents of the University of California |
| 17905592 | METABOLIC ENGINEERING FOR PRODUCTION OF LIPOIC ACID | Non-Final OA | National University of Singapore |
| 17969740 | COXIELLA BURNETII AVIRULENT NINE MILE PHASE II VIABLE BACTERIA AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18034102 | GENETICALLY MODIFIED MICROORGANISM FOR PRODUCING 3-HYDROXYADIPIC ACID AND/OR ALPHA-HYDROMUCONIC ACID, AND METHOD FOR PRODUCING CHEMICAL PRODUCT | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17637057 | APPLICATION OF PSEUDOMONAS AERUGINOSA VACCINE IN TREATING INFECTION ASSOCIATED WITH BURN OR SCALD INJURY | Final Rejection | Sichuan University |
| 17637028 | APPLICATION OF PSEUDOMONAS AERUGINOSA VACCINE IN RESPIRATORY DISEASE | Non-Final OA | Sichuan University |
| 18268032 | BURKHOLDERIA VACCINES AND THERAPEUTICS | Non-Final OA | University of Hawaii |
| 18034239 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | Non-Final OA | Pfizer Inc. |
| 17794744 | INCREASED ETHANOL PRODUCTION BY OVEREXPRESSION OF JID1 IN YEAST | Non-Final OA | DANISCO US INC. |
| 17935466 | BACILLUS SUBTILIS STRAIN, RECOMBINANT BACILLUS SUBTILIS STRAIN AND USE THEREOF | Non-Final OA | Jiangnan University |
| 18697281 | PROBIOTIC ENHANCERS AND USES THEREOF | Non-Final OA | Blis Technologies Limited |
| 17854377 | PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17904155 | PREVENTION AND TREATMENT OF INFECTIONS INCLUDING THOSE CAUSED BY CORONAVIRUS | Final Rejection | IMMODULON THERAPEUTICS LIMITED |
| 18245884 | ANTIBODIES AGAINST STREPTOCOCCAL M PROTEIN | Final Rejection | Aventera Antibodies AB |
| 18017934 | THERAPEUTIC AGENT OR DIAGNOSTIC AGENT FOR CANCER | Final Rejection | JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17998693 | FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY | Non-Final OA | Transmed Gothenburg AB |
| 17754427 | NOVEL SKIN CARE COMPOSITION | Non-Final OA | S-BIOMEDIC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy